🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Subclinical inflammation and renal allograft dysfunction: myth or reality? karger.com/nef/article-ab…

Nailed it 😆

Our research group idibell.cat/en/research/tr… is offering a post doctoral position. idibell.fundanetsuite.com/convocatoriasp…

Si quieres hacer Nefrología, Bellvitge es tu sitio!! 😉 Hospital Universitari Bellvitge | HUB El viernes 21 a las 16h te responderemos todas tus dudas en la Jornada puertas abiertas online. Nefrología HU Bellvitge us05web.zoom.us/j/82194520532?… Passcode: F8YD84

Amb motiu del Dia del Ronyó del passat 13 de març, la Dra. Belén Rubio, nefròloga de l’#hbellvitge participa al programa ‘Línia de Servei’ per parlar sobre la malaltia renal crònica. 📺bit.ly/4hQUDhv #SocialmentResponsables Nefrologia Bellvitge

🗣️ Update in personalized immunosupression 📅 16 de maig 📍 Sala d'actes de l'#hbellvitge 🔗 bit.ly/4cjaG6z Mitjançant la sessió sobre el maneig dels immunosupressors, els casos clínics i les sessions interactives, es vol aprofundir en els desafiaments, les oportunitats

Spanish guidelines for kidney transplantation in highly sensitized pat... sciencedirect.com/science/articl…

Cancer risks in people on dialysis and kidney transplant recipients: a Catalan cohort study, 2003-2021 academic.oup.com/ckj/article/do…

Delayed initiation or reduced initial dose of calcineurin-inhibitors for kidney transplant recipients at high risk … pubmed.ncbi.nlm.nih.gov/40197799/

Real-world evidence regarding cancer, mortality, and graft failure risk with de novo belatacept use among kidney transplant recipients. This study suggests that belatacept use increases risk of PTLD and death. pubmed.ncbi.nlm.nih.gov/40064297/

🆕 Pacients que inspiren | Daniel Rubio Quan la diàlisi va interrompre la seva vida laboral, en Daniel Rubio va decidir obrir-se camí per si sol. Aquest emprenedor tecnològic va convertir la malaltia en un motor de canvi i va col·laborar amb el Servei de Nefrologia de l’HUB en

Resumen de los aspectos fundamentales de las guías nacionales de #trasplante renal con anticuerpos anti-HLA donante-específicos | Spanish guidelines for kidney transplantation in highly sensitized patients with donor-specific anti-HLA antibodies sciencedirect.com/science/articl…

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial kidney-international.org/article/S0085-…

Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression - American Journal of Transplantation amjtransplant.org/article/S1600-…

4th edition of “Update in personalized immunosuppresion” a must-attend meeting in Hospital Universitari Bellvitge | HUB 🇪🇸 organized by Nuria Lloberas and Edoardo Mellili. Proud to represent IATDMCT there!

🙋‍♀️🙋🙋‍♂️¿Quieres saber las fechas destacadas del próximo Congreso Nacional de la #SET2026 en Palexco CORUÑA? 🔥Acabamos de actualizar el apartado #FAQs del Congreso congresoset.com/2026/faqs/

Management of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESI… pubmed.ncbi.nlm.nih.gov/40414085/

Próximo webinar del PROGRAMA FORMATIVO: Sesiones interhospitalarias en trasplante MSD España Sesión 2 📍Miércoles 11 junio 16:30h CEST, emisión virtual acortar.link/S6PUoQ Infección por CMV en el trasplante de órgano sólido ¿Qué hay de nuevo? Modera Josep Maria Cruzado Hospital Universitari Bellvitge | HUB

Presented at #ADASciSessions: Zimislecel is an allogeneic stem cell–derived islet-cell therapy. This phase 1–2 study supports the hypothesis that zimislecel can restore physiologic islet function and thus treat persons with type 1 diabetes. Full study: nej.md/3ZGupbv